AbbVie Inc. sell fenjal
Start price
12.05.22
/
50%
€148.00
Target price
12.05.23
-
Performance (%)
-7.91%
End price
02.06.22
€136.30
Summary
This prediction ended on 02.06.22 with a price of €136.30. With a performance of -7.91%, the SELL prediction by fenjal was trending in the right direction. fenjal has a follow-up prediction for AbbVie Inc., but this time predicts that AbbVie Inc. is a Buy. fenjal has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| AbbVie Inc. | 0.763% | 0.763% | 3.726% |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% |
Comments by fenjal for this prediction
In the thread AbbVie Inc. diskutieren
Sell AbbVie Inc.